Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651949 | 0.97 | MAPT (0.44) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3011147 | 0.91 | TP53 (0.42) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3018440 | 0.90 | TP53 (0.43) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3019075 | 0.89 | TP53 (0.42) | MAPTTP53ALDH1A1LMNAPOLB | |
| SCHEMBL3012409 | 0.89 | MAPT (0.40) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3009996 | 0.89 | MAPT (0.47) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3009736 | 0.89 | MAPT (0.47) | MAPTHSD17B10RECQLUSP2TP53 | |
| SCHEMBL3014108 | 0.89 | MAPT (0.49) | MAPTHSD17B10RECQLUSP2ALDH1A1 | |
| SCHEMBL3013526 | 0.88 | LMNA (0.47) | MAPTTP53ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3018039 | 0.88 | MAPT (0.48) | MAPTHSD17B10RECQLUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | MAPT 18/4885HSD17B10 2553/4885RECQL 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.